In the United States, rifaximin has [[orphan drug]] status for the treatment of [[hepatic encephalopathy]].<ref>{{cite web | url = http://www.emedicine.com/med/TOPIC3185.HTM | title = Hepatic Encephalopathy| accessdate = 2007-02-15 | last = Wolf | first = David C. | date = 2007-01-09| work = [[eMedicine]] | publisher = [[WebMD]] }}</ref> Although high-quality evidence is still lacking, rifaximin appears to be as effective as or more effective than other available treatments for hepatic encephalopathy (such as [[lactulose]]), is better tolerated, and may work faster.<ref>{{cite journal |vauthors=Lawrence KR, Klee JA |title=Rifaximin for the treatment of hepatic encephalopathy |journal=Pharmacotherapy |volume=28 |issue=8 |pages=1019–32 |year=2008 |pmid=18657018 |doi=10.1592/phco.28.8.1019}} [http://www.medscape.com/viewarticle/578716 Free full text with registration] at [[Medscape]].</ref> Rifaximin is taken by mouth. It has minimal side effects, prevents reoccurring encephalopathy, and is associated with high patient satisfaction. Patients are more compliant and satisfied to take this medication than any other due to minimal side effects, prolong remission, and overall cost.<ref>{{cite journal |last1=Kimer |first1=Nina |last2=Krag |first2=Aleksander |last3=Gluud |first3=Lise L. |date=March 2014 |title=Safety, efficacy, and patient acceptability of Rifaximin for hepatic encephalopathy |journal=Patient Preference and Adherence |volume=8 |pages=331–338 |doi=10.2147/PPA.S41565 |pmc=3964161 |pmid=24672227 |access-date=14 April 2016}}</ref>
